MitoxantroneAntibodies, NeoplasmAntibodies, Monoclonal, HumanizedVidarabineLeukemia, Lymphocytic, Chronic, B-CellAntibodies, MonoclonalAntineoplastic AgentsLeukemia, Prolymphocytic, T-CellImmunosuppressive AgentsAntineoplastic Combined Chemotherapy ProtocolsAnthraquinonesLeukemia, ProlymphocyticTreatment OutcomeRemission InductionAntibodies, Monoclonal, Murine-DerivedCytarabinePrednisoneDrug Resistance, NeoplasmTacrolimusATP-Binding Cassette TransportersGraft RejectionKidney TransplantationChlorambucilAntilymphocyte SerumTyphlitisInfectionAntigens, NeoplasmGraft SurvivalSalvage TherapyDrug Resistance, MultipleDrug Administration ScheduleTransplantation ConditioningDoxorubicinMultiple Sclerosis, Relapsing-RemittingCyclophosphamideEtoposideDrug EvaluationPancreas TransplantationGlycoproteinsInjections, SubcutaneousDaunorubicinMycophenolic AcidOpportunistic InfectionsAntigens, CDIdarubicinP-GlycoproteinAmsacrineNeoplasm ProteinsLymphocyte DepletionHistiocytic SarcomaRazoxaneSezary SyndromeTopoisomerase InhibitorsSurvival RateIntercalating AgentsSurvival AnalysisTaxoidsEstramustineNeutropeniaDisease-Free SurvivalTopotecanMelphalanCardiotoxinsVincristineNeoplasm, ResidualLeukemia, MyeloidRecurrenceLymphoma, T-Cell, PeripheralDose-Response Relationship, DrugProstatic NeoplasmsPharmaceutical SolutionsPilot ProjectsDNA Topoisomerases, Type IIAcute DiseaseSteroidsLeukemia, Myeloid, AcuteRetrospective StudiesFollow-Up StudiesHematopoietic Stem Cell Transplantation